|
|
|
| Welcoming over 9,000+ industry professionals, INTERPHEX is the leading global pharmaceutical and biotechnology event that fuses industry innovation with expert-led conference. It's where the newest ideas are shared, technology is unveiled, and the power of science though commercialization comes to life. No matter where you are in the pharmaceutical development lifecycle, INTERPHEX delivers relevant solutions to drive growth and fuel scalability for your business. Learn more |
|
|
|
|
By AR Welch, Editorial & Community Director, Advancing RNA | But much like Dicken's “A Christmas Carol” with its emphasis on how the past and present inform the future, I was struck by six RNA executive’s appreciation for where we have been and currently are as an industry, and how these moments in time are already informing mRNA/RNA’s bright future. |
|
|
|
By Louis Garguilo, Chief Editor, Outsourced Pharma | In 2023, Chief Editor Louis Garguilo proclaimed it was "the year of oligonucleotides," and 2024 would be an incredible growth year for oligos. How are those proclamations panning out? He takes a detailed look, including the important role in the expected growth played by CDMOs. |
|
|
|
By Pooja Sharma, Global Market Insights | According to our new market research, the RNA therapeutics industry is predicted to exceed $31 billion by 2032. This article shares key findings and trends. |
|
|
|
In this Advancing RNA Live clip, Sanofi’s Sumit Luthra highlights the learnings we’ve made to-date about how our processes — both in terms of unit operations and process conditions — inform our LNP composition/heterogeneity. |
|
|
|
|
| Potent Immune Response With Vernal's LNP-mRNAs | Article | By Julia Sakamoto, Vernal Biosciences | As mRNA medicine continues to evolve, understand how trusted manufacturing partners will continue to play a pivotal role in translating innovative concepts into clinical reality. |
|
|
|
|
| Ophthalmic Drug Delivery | Article | By Dr. Tamas Solymosi, Nanoform | Explore the challenges to effective delivery of drugs to the eye, intricacies of ophthalmic drug delivery, and advantages of nanoparticles as an enabling technology for ocular drug-delivery systems. |
|
|
| Compatible Platforms For Microbial Identification | Application Note | Thermo Fisher Scientific | Reduce the time-to-results for microbial identification by taking advantage of the shorter run cycle and off-instrument data analysis provided by this optimized and validated workflow. |
|
|
|
| 2025 BioPlan's 22nd Annual Survey--Biopharmaceutical Manufacturing | For over 20 years, we continue to be the leader in providing the biopharma industry's most comprehensive benchmarking analysis. We invite you to participate in our 22nd Annual Survey in Biopharmaceutical Manufacturing! For all completed, qualified responses, we'll send an Amazon egift card, a copy of the summary results (mid-2025), and our 2025 Top Trends in Biomanufacturing White Paper. |
|
|
.png){kind=logo}
